Last $44.56 USD
Change Today -1.36 / -2.96%
Volume 1.1M
NVO On Other Exchanges
Symbol
Exchange
OTC US
Copenhagen
New York
Mexico
Frankfurt
Frankfurt
As of 8:04 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

novo-nordisk a/s-spons adr (NVO) Snapshot

Open
$45.20
Previous Close
$45.92
Day High
$45.33
Day Low
$44.53
52 Week High
09/18/14 - $49.11
52 Week Low
02/4/14 - $39.24
Market Cap
118.1B
Average Volume 10 Days
1.6M
EPS TTM
--
Shares Outstanding
2.1B
EX-Date
03/21/14
P/E TM
--
Dividend
$0.83
Dividend Yield
1.86%
Current Stock Chart for NOVO-NORDISK A/S-SPONS ADR (NVO)

Related News

No related news articles were found.

novo-nordisk a/s-spons adr (NVO) Details

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation. The company sells its products primarily in North America, China, Japan, Algeria, Argentina, Australia, Brazil, India, Turkey, and European countries through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

40,700 Employees
Last Reported Date: 10/30/14
Founded in 1925

novo-nordisk a/s-spons adr (NVO) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: kr15.2M
President, Chief Operating Officer and Member...
Total Annual Compensation: kr9.0M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer, Executive Vice Preside...
Total Annual Compensation: kr8.1M
Chief Information Officer, Executive Vice Pre...
Total Annual Compensation: kr5.5M
Compensation as of Fiscal Year 2013.

novo-nordisk a/s-spons adr (NVO) Key Developments

Novo Nordisk Proposes Dividend for the Year 2014

At the Annual General Meeting on 19 March 2015, the Board of Directors of Novo Nordisk will propose an 11% increase in dividend to DKK 5.00 per share of DKK 0.20.

Novo Nordisk Receives U.S. Food and Drug Administration Approval for Norditropin Flexpro® 30 mg/3.0 ml for Patients with Growth Hormone Disorders

Novo Nordisk announced the U.S. Food and Drug Administration (FDA) approval of Norditropin (somatropin [rDNA origin] injection) FlexPro® 30 mg/3.0 mL, a prefilled injection pen for patients with growth hormone-related disorders. The FlexPro® 30 mg/3.0 mL device complements the existing portfolio of Norditropin® FlexPro® products available in 5 mg/1.5 mL, 10 mg/1.5 mL and 15 mg/1.5 mL pens. The availability of four different strengths of Norditropin FlexPro enhances physicians' ability to better address the unique needs of appropriate patients on treatment. Each Norditropin FlexPro pen is prefilled with Norditropin, and is color coded to differentiate the various strengths. Novo Nordisk plans to make Norditropin FlexPro 30 mg/3.0 mL available by April 2015.

Novo Nordisk Receives Positive Opinion from the European Regulatory Authorities for Saxenda® (Liraglutide 3 mg) for the Treatment of Obesity

Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion for the use of Saxenda® (liraglutide 3 mg) for the treatment of obesity. Saxenda®, the intended brand name of liraglutide 3 mg, is a once-daily glucagon-like peptide-1 (GLP-1) analogue, with 97% homology to naturally occurring human GLP-1, a hormone involved in appetite regulation. The CHMP positive opinion recommends that Saxenda® will be indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of 30 kg/m2 (obese), or 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. The CHMP positive opinion is based on data from clinical trials of Saxenda®, including the phase 3 SCALETM clinical development programme, which involved more than 5,000 people with obesity (BMI 30 kg/m2), or who were overweight (BMI 27 kg/m2) with comorbidities. The company expected to receive marketing authorisation from the European Commission within two to three months. Subject to the Commission's approval Novo Nordisk expects to launch Saxenda® in several European markets starting in 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVO:US $44.56 USD -1.36

NVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $60.35 USD -2.77
Biogen Idec Inc $389.16 USD +35.91
Bristol-Myers Squibb Co $60.27 USD -0.87
Eli Lilly & Co $72.00 USD -0.11
Reckitt Benckiser Group PLC 5,630 GBp -90.00
View Industry Companies
 

Industry Analysis

NVO

Industry Average

Valuation NVO Industry Range
Price/Earnings 27.3x
Price/Sales 8.2x
Price/Book 18.5x
Price/Cash Flow 21.8x
TEV/Sales 6.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit www.novonordisk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.